Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a cutting-edge biopharmaceutical company focused on developing targeted therapeutics for devastating diseases with inadequate treatment options. The company leverages a proprietary portfolio of antibodies and immunomodulators to create novel, disease-specific therapies that modify the body's immune response. Founded with the belief that harnessing the immune system's power could overcome significant barriers in drug development, Celldex has built a robust pipeline of therapeutic antibodies, antibody-drug conjugates, immune system modulators, and vaccines.
Celldex is actively engaged in clinical trials for its promising pipeline products, including Varlilumab, CDX-301, CDX-1140, CDX-0159/Anti-KIT Program (barzolvolimab), and CDX-527. These therapies target conditions like breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer, focusing on specific patient populations with high unmet medical needs.
Recently, Celldex reported positive results from its Phase 2 clinical trial of barzolvolimab in patients with chronic spontaneous urticaria (CSU), a condition unresponsive to standard antihistamines and biologics. The study demonstrated significant improvements in patient symptoms, paving the way for Phase 3 trials. Additional clinical studies are underway for barzolvolimab in chronic inducible urticaria (CIndU), prurigo nodularis (PN), and eosinophilic esophagitis (EOE).
Celldex's financial health is robust, with substantial capital to support ongoing research and development. The company's recent public offering raised significant funds, ensuring the continuation of its innovative programs through 2027. Strategic partnerships, including collaborations with renowned institutions like Rockefeller University, further bolster Celldex's research endeavors.
Celldex Therapeutics is at the forefront of biotech innovation, striving to deliver transformative treatments for severe inflammatory, allergic, autoimmune, and other debilitating diseases. Stay updated with the latest developments and news by visiting www.celldex.com.
Celldex Therapeutics (NASDAQ:CLDX) reported Q3 2020 financials, revealing a net loss of $14.2 million, or ($0.36) per share. Revenues increased to $0.7 million, driven by a milestone payment from Rockefeller University. The company initiated two Phase 1b studies for CDX-0159 in chronic spontaneous and inducible urticaria, alongside advancing bispecific candidate CDX-527. Despite cash reserves decreasing to $199.6 million, Celldex maintains that its funding is sufficient to meet operational needs through 2023.
Celldex Therapeutics (Nasdaq:CLDX) has initiated a Phase 1b clinical trial for CDX-0159, targeting chronic spontaneous urticaria (CSU). The trial, which is randomized and double-blind, will assess the safety and efficacy of multiple doses of CDX-0159 in approximately 40 patients with CSU unresponsive to antihistamines. Previous studies demonstrated CDX-0159's favorable safety profile and significant reductions in plasma tryptase levels, indicating its potential as a disease-modifying therapy. Results from the study are anticipated in the latter half of 2021.
Celldex Therapeutics (NASDAQ: CLDX) will participate in two upcoming virtual fireside chats. The first is at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 10:40 AM ET, followed by the HC Wainwright & CO 22nd Annual Global Investment Virtual Conference on September 16, 2020, at 9:00 AM ET. Webcasts of both presentations will be available on the Celldex website, with replays accessible for fourteen days post-event.
Celldex Therapeutics (Nasdaq: CLDX) has initiated enrollment for a Phase 1 open-label study of CDX-527, aimed at patients with advanced solid tumors. CDX-527 is a novel bispecific antibody designed to enhance anti-tumor T cell responses by combining PD-L1 blockade with CD27 costimulation. The trial will evaluate safety, maximum tolerated dose, and anti-tumor activity across various endpoints, enrolling approximately 90 patients. Previous data suggests CDX-527 could outperform existing treatments, bolstering its potential in the Celldex pipeline.
Celldex Therapeutics (Nasdaq: CLDX) is set to announce its second quarter 2020 financial results on August 6, 2020, after market close. A conference call will follow at 4:30 p.m. EDT, where executives will discuss the financial outcomes and provide updates on ongoing research and development initiatives for the remainder of 2020. The call will be accessible via the company’s website, and a replay will be available post-event. Celldex focuses on developing targeted therapeutics for severe diseases, utilizing immunotherapies and biologics to enhance treatment options for cancer and other illnesses.
Celldex Therapeutics (CLDX) has successfully closed an underwritten public offering of 15,384,614 shares at $9.75 each, generating approximately $150 million in gross proceeds. This includes the full exercise of the underwriters' option for additional shares. The company affirms that the funds will be sufficient to meet its working capital and operational needs through 2023. The offering was managed by Cantor Fitzgerald & Co., with H.C. Wainwright & Co. as co-manager. The offering is compliant with SEC regulations, and details are available on the SEC's website.
Celldex Therapeutics (Nasdaq: CLDX) has priced its underwritten public offering of 13,377,926 shares at $9.75 each, aiming to raise about $130.4 million. The offering includes a 30-day option for the underwriter to purchase an additional 2,006,688 shares. Proceeds will support ongoing clinical and preclinical development of product candidates and general corporate purposes. The offering is set to close on June 18, 2020, subject to customary conditions. The offering follows a prospectus supplement filed with the SEC on June 12, 2020.
Celldex Therapeutics (Nasdaq: CLDX) announced a proposed underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of the shares. The company aims to utilize the proceeds for clinical and preclinical development of its product candidates and general corporate purposes. The final terms will depend on market conditions, and there is no guarantee regarding the completion or terms of the offering. Cantor Fitzgerald & Co. is the sole book-running manager for the offering.
Celldex Therapeutics (NASDAQ: CLDX) announced positive results from a Phase 1 study of its KIT inhibitor, CDX-0159, targeting mast cell-driven diseases. Presented at the EAACI Annual Congress 2020, the study showed CDX-0159 induced significant and long-lasting reductions in plasma tryptase levels, indicating effective mast cell suppression. The favorable safety profile and promising data support further development in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU). Future studies are expected to start later this year, enhancing treatment options for patients.
Celldex Therapeutics (NASDAQ:CLDX) reported significant progress in its pipeline during Q1 2020, despite COVID-19 challenges. The company completed enrollment in the Phase 1 study of its KIT inhibitor, CDX-0159, set for presentation at the EAACI Annual Congress 2020. Celldex plans to expand CDX-0159's development for chronic urticaria and is preparing for a Phase 1 study of CDX-527 in advanced cancers. Q1 2020 financials showed revenues of $2.7 million, primarily from a $1.8 million milestone payment, while net loss decreased to $12.6 million. Celldex's cash is sufficient to fund operations into Q2 2021.
FAQ
What is the current stock price of Celldex Therapeutics (CLDX)?
What is the market cap of Celldex Therapeutics (CLDX)?
What is Celldex Therapeutics' primary focus?
What are the key products in Celldex's pipeline?
What recent achievements has Celldex announced?
What diseases does Celldex target?
How is Celldex financially positioned?
Who are Celldex's strategic partners?
What is barzolvolimab?
Where can I find more information on Celldex's clinical trials?
What is Celldex's approach to drug development?